Repository logo
 
Publication

Five-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) survey

dc.contributor.authorAllwood, Brian
dc.contributor.authorGillespie, R
dc.contributor.authorBateman, Mary
dc.contributor.authorOlckers, Helena
dc.contributor.authorBarata, Luis Taborda
dc.contributor.authorCalligaro, Gregory L
dc.contributor.authorvan Zyl-Smit, Richard
dc.contributor.authorCooper, Christopher B
dc.contributor.authorBeyers, N
dc.contributor.authorBateman, Eric
dc.date.accessioned2020-02-21T11:29:46Z
dc.date.available2020-02-21T11:29:46Z
dc.date.issued2018-02-01
dc.description.abstractBackground. A community-based prevalence survey performed in two suburbs in Cape Town, South Africa (SA), in 2005, using the international Burden of Obstructive Lung Disease (BOLD) method, confirmed a prevalence of chronic airflow obstruction (CAO) in 23.1% of adults aged >40 years. Objectives. To study the clinical course and prognosis over 5 years of patients with CAO identified in the 2005 survey. Methods. Patients with CAO in 2005 were invited to participate. Standard BOLD and modified questionnaires were completed. Spirometry was performed using spirometers of the same make as in 2005. Results. Of 196 eligible participants from BOLD 2005, 45 (23.0%) had died, 8 from respiratory causes, 10 from cardiovascular causes and 6 from other known causes, while in 21 cases the cause of death was not known. On multivariate analysis, only age and Global initiative for Obstructive Lung Disease (GOLD) stage 4 disease at baseline were significantly associated with death. Of the 151 survivors, 11 (5.6% of the original cohort) were unavailable and 33 (16.8%) declined or had medical exclusions. One hundred and seven survivors were enrolled in the follow-up study (54.6%, median age 63.1 years, 45.8% males). Post-bronchodilator spirometry performed in 106 participants failed to confirm CAO, defined as a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of <0.7, in 16 participants (15.1%), but CAO was present in 90. The median decline in FEV1 was 28.9 mL/year (interquartile range –54.8 - 0.0) and was similar between GOLD stages. The median total decline in FVC was 75 mL, and was significantly greater in GOLD stage 1 (–350 mL) than in stages 2 or 3 (–80 mL and +140 mL, respectively; p<0.01). Fifty-eight participants with CAO in 2005 (64.4%) remained in the same GOLD stage, while 21 (23.3%) deteriorated and 11 (12.2%) improved by ≥1 stage. Only one-third were receiving any treatment for chronic obstructive pulmonary disease (COPD). Conclusions. The prevalence, morbidity and mortality of CAO and COPD in SA are high and the level of appropriate treatment is very low, pointing to underdiagnosis and inadequate provision of and access to effective treatments and preventive strategies for this priority chronic non-communicable disease.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.7196/SAMJ.2017.v108i2.12688pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/9440
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherHealth and Medical Publishing Grouppt_PT
dc.relationA CLINICAL, RADIOLOGICAL AND PATHOPHYSIOLOGICAL STUDY OF CHRONIC OBSTRUCTIVE LUNG DISEASE IN A COHORT OF PATIENTS WITH HIV INFECTION RECEIVING ANTIRETROVIRAL TREATMENT
dc.relation.publisherversionhttp://www.samj.org.za/index.php/samj/article/view/12196pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectCOPDpt_PT
dc.titleFive-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) surveypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleA CLINICAL, RADIOLOGICAL AND PATHOPHYSIOLOGICAL STUDY OF CHRONIC OBSTRUCTIVE LUNG DISEASE IN A COHORT OF PATIENTS WITH HIV INFECTION RECEIVING ANTIRETROVIRAL TREATMENT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBSAB%2F976%2F2010/PT
oaire.citation.endPage143pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage138pt_PT
oaire.citation.titleSouth African Medical Journalpt_PT
oaire.citation.volume108pt_PT
person.familyNameTaborda Barata
person.familyNamevan Zyl-Smit
person.familyNameBATEMAN
person.givenNameLuis
person.givenNameRichard
person.givenNameERIC
person.identifier104007
person.identifier.ciencia-id1E1F-8A43-055B
person.identifier.orcid0000-0001-6649-8890
person.identifier.orcid0000-0002-4115-5362
person.identifier.orcid0000-0002-5064-5849
person.identifier.scopus-author-id15128160500
person.identifier.scopus-author-id6603972670
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication3f1ad371-56e3-4fda-9409-748e355a0de1
relation.isAuthorOfPublication111606e3-876e-4fd7-8034-7659896d3a07
relation.isAuthorOfPublicationd9587135-e478-4a1c-a9a2-3a74380d5d17
relation.isAuthorOfPublication.latestForDiscoveryd9587135-e478-4a1c-a9a2-3a74380d5d17
relation.isProjectOfPublication2cf75e11-0482-4a9d-a505-4a7806979960
relation.isProjectOfPublication.latestForDiscovery2cf75e11-0482-4a9d-a505-4a7806979960

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Allwood et al (COPD follow up) 2018.pdf
Size:
237.2 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: